Selective EP2 Receptor Antagonists for Targeted Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by the EP2 receptor, such as inflammation and neurodegeneration, lack specificity and can have adverse effects, necessitating the development of targeted EP2 receptor antagonists.
Innovation Solution
Development of compounds that selectively inhibit the EP2 receptor, formulated into pharmaceutical compositions for various administration routes, including enteral, parenteral, topical, and pulmonary, to treat a range of conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current NSAIDs are used to inhibit COX-2, then inflammation and pain symptoms are relieved, but selectivity is poor and adverse effects occur
Solution Approach 1:
The patent segments the COX-2 inhibition pathway by targeting a specific downstream prostaglandin receptor (EP2) rather than blocking the entire COX-2 cascade. This selective receptor antagonism maintains therapeutic effectiveness while reducing off-target adverse effects associated with nonselective COX inhibition.
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular structures (Formula I and Formula II) that selectively bind to the EP2 receptor subtype. This structural specificity ensures targeted action at the desired receptor while sparing other prostaglandin receptors and COX isoforms, thereby reducing systemic adverse effects.
2Adaptability or versatility
If nonselective COX inhibition is used, then broad anti-inflammatory effects are achieved, but tissue injury pathways are not selectively modulated
Solution Approach 1:
The patent divides the inflammatory pathway into distinct segments by targeting the EP2 receptor specifically. This allows selective modulation of PGE2-mediated inflammatory responses while preserving other COX-2 signaling pathways that may have protective or beneficial functions.
Solution Approach 2:
The invention changes the parameter of selectivity by designing compounds with specific chemical structures (Formula I and Formula II) that exhibit preferential binding to EP2 receptors. This structural optimization achieves high selectivity ratios (e.g., EP2/EP4 selectivity >10:1) while maintaining broad applicability across multiple inflammatory conditions.
3Object-affected harmful factors
If EP2 receptor antagonists are developed, then selective inhibition is achieved, but compound specificity and pharmacokinetic optimization are challenging
Solution Approach 1:
The patent employs local quality by defining specific structural features in Formula I and Formula II that confer EP2 selectivity. These localized structural modifications (specific substituent patterns at defined positions) enable high receptor specificity while simplifying the overall drug development process through structure-activity relationship (SAR) optimization.
Solution Approach 2:
The invention optimizes multiple parameters simultaneously including receptor binding affinity, selectivity ratio, and pharmacokinetic properties. By systematically adjusting molecular parameters (substituent types, positions, and configurations in the defined formulas), the patent achieves compounds with improved toxicity profiles and optimized pharmacokinetic characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit EP2 receptor activity, reducing inflammation and associated symptoms in conditions like rheumatoid arthritis, Alzheimer's disease, and cancer, with minimal toxicity and improved pharmacokinetic profiles.
Implementation Method 1
certain compounds and compositions inhibit the prostaglandin E2 receptor subtype EP2
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.